Clinical Trial Update: Single-centre Study of Everolimus as GvHD Prophylaxis After Post-Transplantation Cyclophosphamide After Allogeneic SCT [Phase 2]

View source ↗

Summary

Phase 2 single-centre trial evaluating everolimus as prophylaxis for graft-versus-host disease after post-transplant cyclophosphamide in allogeneic stem cell tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: University of Cologne | Conditions: Graft-versus-Host Disease | Phase 2 | Status: COMPLETED